Jackson Creek Investment Advisors LLC Makes New Investment in Hims & Hers Health, Inc. (NYSE:HIMS)

Jackson Creek Investment Advisors LLC purchased a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 53,108 shares of the company's stock, valued at approximately $1,284,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Quest Partners LLC raised its stake in shares of Hims & Hers Health by 22.6% during the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company's stock worth $81,000 after buying an additional 807 shares during the period. Stonekeep Investments LLC raised its position in Hims & Hers Health by 5.5% during the fourth quarter. Stonekeep Investments LLC now owns 16,952 shares of the company's stock worth $410,000 after acquiring an additional 882 shares during the period. Principal Securities Inc. lifted its holdings in Hims & Hers Health by 48.2% during the fourth quarter. Principal Securities Inc. now owns 3,079 shares of the company's stock valued at $74,000 after purchasing an additional 1,002 shares in the last quarter. Victory Capital Management Inc. grew its position in shares of Hims & Hers Health by 1.9% in the fourth quarter. Victory Capital Management Inc. now owns 52,579 shares of the company's stock valued at $1,271,000 after purchasing an additional 1,002 shares during the period. Finally, Cadent Capital Advisors LLC increased its stake in shares of Hims & Hers Health by 1.5% during the fourth quarter. Cadent Capital Advisors LLC now owns 72,160 shares of the company's stock worth $1,745,000 after purchasing an additional 1,060 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Remove Ads

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 4,213 shares of the business's stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $29.98, for a total value of $126,305.74. Following the completion of the sale, the chief financial officer now owns 128,365 shares of the company's stock, valued at $3,848,382.70. The trade was a 3.18 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Soleil Boughton sold 4,152 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total value of $251,984.88. Following the transaction, the insider now directly owns 157,345 shares in the company, valued at approximately $9,549,268.05. This represents a 2.57 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,062,011 shares of company stock valued at $36,892,724 over the last ninety days. Corporate insiders own 17.71% of the company's stock.

Wall Street Analysts Forecast Growth

HIMS has been the topic of a number of research reports. Bank of America reaffirmed an "underperform" rating and issued a $21.00 price target on shares of Hims & Hers Health in a research note on Thursday. Needham & Company LLC boosted their price objective on Hims & Hers Health from $31.00 to $61.00 and gave the company a "buy" rating in a report on Tuesday, February 25th. Canaccord Genuity Group boosted their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a research report on Wednesday, February 19th. Morgan Stanley cut shares of Hims & Hers Health from an "overweight" rating to an "equal weight" rating and raised their price objective for the stock from $42.00 to $60.00 in a report on Tuesday, February 18th. Finally, Leerink Partners increased their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research note on Tuesday, February 25th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $37.23.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock traded up $0.05 on Monday, reaching $36.00. 8,891,770 shares of the company were exchanged, compared to its average volume of 13,172,629. The company's 50-day moving average is $37.64 and its two-hundred day moving average is $27.60. Hims & Hers Health, Inc. has a 1-year low of $11.20 and a 1-year high of $72.98. The firm has a market cap of $8.00 billion, a price-to-earnings ratio of 81.58 and a beta of 1.37.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping analysts' consensus estimates of $0.09 by $0.02. The firm had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. As a group, sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.